MedApp S.A. has become one of three finalists in the category Health and Biotechnology of the Start-up Challenge 2021. Out of 170 submitted applications, the best 18 companies made it to the finals and presented their solutions at the European Economic Congress during the European Tech and Start-up Days in Katowice.
On 21 September 2021, the founders and leaders of the most interesting Polish and European start-ups stood on the stage of the European Economic Congress for the sixth time. Among them, in the category HEALTH & BIOTECHNOLOGY: medicine, health, medical technology, pharmacy, biotechnology was MedApp S.A.
“I am glad that we had the opportunity to present our solutions to business and economic practitioners with international experience during the European Economic Congress. My team and I are honored to be one of the three finalists in the category Health and Biotechnology. I believe that our products, which are being developed with the use of mixed reality, artificial intelligence, and Big Data analytics, are the future of medicine. Congratulations to all participants and winners of the Start-up Challenge 2021 Winner,” says Krzysztof Mędrala – CEO at MedApp SA.
The key products offered by our company are: CarnaLife Holo, CarnaLife System, Digital Clinic, HoloComm.
CarnaLife Holo is a certified innovative technology that supports planning and execution of complex medical procedures. With the help of Microsoft’s HoloLens 2 goggles, the doctor sees in real 3D space a hologram that reflects the imaged anatomical area. The doctor is able to interact with the displayed hologram. CarnaLife Holo is present in 18 medical facilities in Poland and abroad, and it has already been used in 100 medical procedures of different specializations.
CarnaLife System is an advanced telemedicine platform that allows a doctor to assess and monitor the health of their patients and conduct consultations at any time of the day and at any place. The system is supported by more than 20 remote measurement devices. Examination results are analyzed round the clock using AI algorithms and Big Data analytics. The system has been implemented in 16 medical facilities. On the basis of this solution, the Digital Clinic was created, which is a product aimed directly at patients and individual users.
HoloComm is an engaging solution for remote 3D presentation of products, content, data and more, using Microsoft HoloLens 2 goggles.
In total, in the first half of 2021, MedApp generated revenues of PLN 5,472,000 and a net profit of PLN 1,838,000. The results generated in the first half of 2021 are similar to the results the Company generated in the whole 2020, when revenues amounted to PLN 6,025,000 and net profit to PLN 1,915,000. The company’s strengths include the support of the Science Advisory Board consisting of recognized specialists in medical innovation, and cooperation with international technology and medical leaders such as: Microsoft, GE Healthcare or Johnson & Johnson.
In 2021, MedApp SA is planning to debut on the main market of the Warsaw Stock Exchange.
Read more See similar articles:
MedApp S.A., is the partner of the nationwide contest for schoolgirls “Become an Ambassador”.
On October 11, 2021, in celebration of the International Day of the Girl, 12 finalists of the nationwide contest for schoolgirls “Become an Ambassador” were given the opportunity to learn about the world of diplomacy by playing the role of an Ambassador in one of the participating Embassies.
The results generated in H1 2021 by MedApp S.A. are similar to the results the Company achieved for the whole of 2020. The interview with Krzysztof Mędrala, CEO of MedApp S.A.
In connection with the publication of the Interim Report for Q2 2021 on September 12, 2021, we invite you to watch the interview with Krzysztof Mędrala, CEO of MedApp S.A. according to Company’s activities realized in the reporting period and the financial results achieved in H1 2021.
MedApp significantly increases its business scale in Q2 2021.
The Cracow-based company, offering innovative technological solutions in medicine (medtech), achieved a net result in the first half of this year, similar to the level for the whole of last year.